Information updates

Updated and new ASCIA HAE resources

The ASCIA Hereditary Angioedema (HAE) Position Paper and Management Plan have been updated and are now available on the ASCIA website: www.allergy.org.au/hp/papers/hereditary-angioedema

The urgent updating of these documents is due to Takhzyro® (lanadelumab) being PBS listed for HAE from 1st December 2021.

We have also taken this opportunity to make other product related changes, including:

  • Removal of the product name ‘Firazyr’ as the current product is generic ‘Icatibant’.
  • A statement regarding Danazol (Azol) being discontinued in January 2020 in Australia.
  • Replacing the Berinert® order form with an updated version on page 25.  
  • Updating of the ASCIA HAE Management Plan on page 23 to include Takhzyro® (lanadelumab) and remove the product name ‘Firazyr’.

A new ASCIA HAE Frequently Asked Questions (FAQ) for patients, consumers and carers has been developed in October 2021 and is available on the ASCIA website www.allergy.org.au/patients/immunodeficiencies/hae

This news item was issued on 13 January 2022 by the Australasian Society of Clinical Immunology and Allergy (ASCIA), the peak professional body for clinical immunology and allergy in Australia and New Zealand.

Mod ASCIA Member
Donate to AIFA
go to NAC website
About ASCIA

ASCIA is the peak professional body of clinical immunology and allergy in Australia and New Zealand
ASCIA promotes and advances the study and knowledge of allergy and other immune diseases

Quick Links

About ASCIA

ASCIA is a registered trademark of the Australasian Society of Clinical Immunology and Allergy. All content is subject to copyright for the Australasian Society of Clinical Immunology and Allergy. Read more...

The content for the website is developed and approved by ASCIA Committee and ASCIA Working Party Members. Read more...

Disclaimer I Privacy

The ASCIA website is intended for use by ASCIA members, health professionals and the general public. The content provided is for education, communication and information purposes only and is not intended to replace or constitute medical advice or treatments. Read more...

ASCIA respects your privacy. Read our privacy policy here...

Sponsors | Advertising

ASCIA does not endorse products from sponsoring organisations, nor is it influenced by sponsoring organisations with regard to the content of education programs and websites. 

The ASCIA website does not accept advertising. Any link to a third-party website does not imply any endorsement by ASCIA.

Information Partner

Official Information Partner of Healthdirect Australia